TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15731540
Drug: Histamine2-receptor antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Histamine2-receptor antagonist (ranitidine 300 mg/day)
Study: 15731540
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor (rabeprazole 10 mg/day)
Study: 11755937
Drug: tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tibolone 2.5 mg/day (n=20)
Study: 11755937
Drug: 0.625 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/day conjugated equine oestrogens plus continuous medroxyprogesterone acetate 5 mg/day (n=23)
Study: 9652276
Drug: In-line intravenous
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-line intravenous filters
Study: 9652276
Drug: No in-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: No in-line intravenous filters
Study: 7892022
Drug: Amitriptyline 75
Normalized name: amitriptyline 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 75 mg (slow-release formulation)
Study: 3053312
Drug: Low-dose antacid
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose antacid regimen
Study: 26118386
Drug: High-dose tranexamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tranexamic acid (4 g intravenously then 1 g/h for 6 h)
Study: 22695134
Drug: Weekly UV-B
Normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly UV-B in a tanning bed (group A)
Study: 22695134
Drug: 1520-IU/d vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1520-IU/d vitamin D supplement (group B)
Study: 18946298
Drug: 7 mg
Normalized name: pectin 7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 mg spinal bupivacaine with intravenous phenylephrine infusion (0.25 microg . kg(‐1) . min(‐1))
Study: 18946298
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg spinal bupivacaine with intravenous placebo infusion
Study: 8857917
Drug: Medium cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium cholesterol diet (350 mg)
Study: 8857917
Drug: High cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High cholesterol diet (650 mg)
Study: 1638340
Drug: Trichlormethiazide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trichlormethiazide (4 mg/day)
Study: 1638340
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment with close follow-up)
Study: 3859954
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg PGE2 gel placed retroamnially by means of a balloon catheter
Study: 6594721
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg PGE2 applied endocervically
Study: 6594721
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg PGE2 applied endocervically
Study: 3859954
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg PGE2 placed intravaginally in form of a single vaginal tablet
Study: 22278334
Drug: CG100649 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CG100649 (2 mg)
Study: 22278334
Drug: CG100649 (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: CG100649 (8 mg)
Study: 10075616
Drug: Inhaled beclomethasone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone, 200 microg twice daily
Study: 10075616
Drug: Oral montelukast,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral montelukast, 10 mg once daily at bedtime
Study: 7734138
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of tyramine to raise systemic blood pressure
Study: 1755532
Drug: Patient Controlled
Normalized name: PATIENT CONTROLLED ANALGESIA VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient Controlled Analgesia (PCA) with morphine (2 mg bolus, lock-out 5 min in recovery/intensive care, 15 min in surgical ward)
Study: 1755532
Drug: Epidural Bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural Bupivacaine + Morphine (EBM) with bupivacaine (0.25%) and morphine (60 micrograms/ml) infused via epidural catheter for approximately 72 hours
Study: 1755532
Drug: Epidural Morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural Morphine (EM) with morphine (0.05 mg/kg in 10 ml saline) injected on request up to the 3rd postoperative day
Study: 6120272
Drug: Sulphinpyrazone 400
Normalized name: Sulphinpyrazone
DrugBank: Sulfinpyrazone (DB01138)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulphinpyrazone 400 mg twice daily
Study: 26595551
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine at the time of infliximab infusion
Study: 26595551
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine midway between infliximab infusions
Study: 23471234
Drug: Recombinant t-PA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant t-PA (0, 40, 200, and 1000 ng/mL)
Study: 23471234
Drug: Intra-arterial bradykinin
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial bradykinin infusion
Study: 23471234
Drug: Intra-arterial bradykinin
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial bradykinin infusion with enalapril
Study: 20973856
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR + nicotine lozenge
Study: 28922651
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch + nicotine lozenge
Study: 12869836
Drug: PRO 2000
Normalized name: PRO 2000
DrugBank: PRO 2000 (DB05385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO 2000 Gel
Study: 12869836
Drug: BufferGel and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: BufferGel and PRO 2000 Gel
Study: 11031076
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline solutions (2 and 5% NaCl) and thirsting
Study: 11031076
Drug: Oral water
Normalized name: Oral Wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral water ad libitum
Study: 9100162
Drug: Sulodexide (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulodexide (600 lipoprotein-lipase releasing units, intramuscularly, daily for 28 days)
Study: 8261692
Drug: Felodipine ER
Normalized name: Felodipine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine ER 5 mg od
Study: 8261692
Drug: Felodipine PT
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine PT 2.5 mg bid
Study: 30041437
Drug: High-Protein diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Protein diet with three whole eggs per day (1.4 g protein kg‐1 day‐1)
Study: 30041437
Drug: Normal-Protein diet
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-Protein diet void of eggs (0.8 g protein kg‐1 day‐1)
Study: 27936999
Drug: Single-pill irbesartan/amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-pill irbesartan/amlodipine combination-based therapy for 12 weeks
Study: 25166215
Drug: Pterygopalatine fossa
Normalized name: Fossaoprin SPG2 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pterygopalatine fossa injection with 1% xylocaine and 1:100,000 adrenaline
Study: 25166215
Drug: Control (contralateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (contralateral side without injection)
Study: 19238327
Drug: Talactoferrin 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talactoferrin 4.5 g/day
Study: 19238327
Drug: Talactoferrin 9
Normalized name: Talactoferrin alfa
DrugBank: Talactoferrin alfa (DB05426)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talactoferrin 9 g/day
Study: 18547273
Drug: Duodenal levodopa/carbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duodenal levodopa/carbidopa infusion
Study: 7913683
Drug: beta‐adrenoceptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta‐adrenoceptor antagonists (beta AA)
Study: 7913683
Drug: calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: calcium channel blockers (CCB)
Study: 24318863
Drug: Planned treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Planned treatment preceded by pretreatment genetic analysis
Study: 24318863
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX regimen in planned treatment group
Study: 24318863
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI regimen in planned treatment group
Study: 24318863
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX regimen in conventional treatment group
Study: 24318863
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI regimen in conventional treatment group
Study: 17408924
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of oral clindamycin (600 mg) administered preoperatively
Study: 17408924
Drug: Clindamycin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin administered preoperatively with continued therapy for 5 days
Study: 17408924
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of oral clindamycin (600 mg)
Study: 17408924
Drug: Clindamycin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (single dose or 5-day therapy)
Study: 10205637
Drug: Folifer-Z tablets
Normalized name: Z-160
DrugBank: Z-160 (DB12743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folifer-Z tablets
Study: 10205637
Drug: Fefol-Z capsules
Normalized name: Z-160
DrugBank: Z-160 (DB12743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fefol-Z capsules
Study: 2472826
Drug: Chemotherapy (streptozotocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (streptozotocin plus 5-fluorouracil)
Study: 28533200
Drug: Beliefs about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beliefs about Medicines Questionnaire (quantitative assessment)
Study: 26522042
Drug: Clinpro XT
Normalized name: Clinpro 5000
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clinpro XT light-curable fluoride varnish applied to buccal surfaces adjacent to brackets
Study: 20528216
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (100 μg per day)
Study: 17536122
Drug: Moderate multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate multivitamin and mineral supplementation (vitamin C 150.0 mg/day, vitamin E 24.0 mg/day, beta-carotene 4.8 mg/day)
Study: 11376277
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of SH U 508A (1 mL/min)
Study: 11376277
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of SH U 508A
Study: 11376277
Drug: Individualized infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized infusion of SH U 508A
Study: 8433354
Drug: Detection behaviors
Normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection behaviors (e.g., cholesterol check)
Study: 8433354
Drug: Promotion behaviors
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Promotion behaviors (e.g., eating a low-fat diet)
Study: 29843755
Drug: G +
Normalized name: Citracal 250 mg + D
Approvals — FDA: no, EMA: no, PMDA: no
Description: G + MK (gemcitabine + MK-0646)
Study: 29843755
Drug: G +
Normalized name: Citracal 250 mg + D
Approvals — FDA: no, EMA: no, PMDA: no
Description: G + MK + E (gemcitabine + MK-0646 + erlotinib)
Study: 29843755
Drug: G +
Normalized name: Citracal 250 mg + D
Approvals — FDA: no, EMA: no, PMDA: no
Description: G + E (gemcitabine + erlotinib)
Study: 25592781
Drug: IFN and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN and low doses of MTX
Study: 23418958
Drug: Standard cardiovascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cardiovascular treatment according to Dutch guidelines
Study: 22029856
Drug: Roflumilast 500
Normalized name: ROFLUMILAST 500MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast 500 mcg
Study: 16995545
Drug: Customized aspheric
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Customized aspheric treatment zone (CATz)
Study: 14722370
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron supplementation (60 mg)
Study: 14722370
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly iron supplementation (60 mg)
Study: 9163024
Drug: Antiviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral treatment with aciclovir
Study: 1351888
Drug: nebivolol 5
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebivolol 5 mg once daily for 4 weeks
Study: 6584561
Drug: Carminomycin (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carminomycin (18 mg/m2)
Study: 6584561
Drug: 4'-epidoxorubicin (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4'-epidoxorubicin (90 mg/m2)
Study: 30391573
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy with 45 Gy/30 twice-daily fractions over 19 days
Study: 30391573
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy with 66 Gy/33 once-daily fractions over 45 days
Study: 30391573
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (both groups)
Study: 25654629
Drug: Individualized program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized program including exercise therapy plus risk factor modification for 12 weeks
Study: 20880729
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg plus placebo
Study: 15235556
Drug: 0.2% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% ropivacaine combined with sufentanil at a dose of 0.5 microg/ml(‐1) (group A)
Study: 15235556
Drug: 0.2% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% ropivacaine combined with sufentanil at a dose of 0.75 microg/ml(‐1) (group B)
Study: 15235556
Drug: 0.2% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% ropivacaine combined with sufentanil at a dose of 1 microg/ml(‐1) (group C)
Study: 2169378
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose concentration maintained at 4.5 mmol/l (euglycaemia)
Study: 2169378
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose concentration maintained at 3.5 mmol/l (mild hypoglycaemia)
Study: 224997
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (cyclophosphamide, doxorubicin, and imidazole carboximide)
Study: 224997
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with cycle-active therapy (vincristine, hydroxyurea, and methotrexate)
Study: 6660827
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution, 10 ml per 1000 g of patient weight injected into the peritoneal cavity before closing the incision.
Study: 6660827
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no saline solution injection).
Study: 29398576
Drug: Real tVNS
Normalized name: TVN-102
DrugBank: TVN-102 (DB16990)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real tVNS treatment
Study: 29398576
Drug: Sham tVNS
Normalized name: TVN-102
DrugBank: TVN-102 (DB16990)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham tVNS treatment
Study: 25152605
Drug: NSAID-muscovite group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID-muscovite group (3 g of muscovite + 75 mg slow-release diclofenac, twice daily for 14 d)
Study: 25152605
Drug: NSAID control
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID control group (75 mg slow-release diclofenac, twice daily for 14 d)
Study: 20016013
Drug: Corrected fractional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corrected fractional iron absorption in children
Study: 15630172
Drug: Liposomal lactoferrin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal lactoferrin, 319 mg per day for four weeks
Study: 11789395
Drug: Perindopril +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril + indapamide treatment
Study: 9435041
Drug: Imipenem/cilastatin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin (1.5 g/day)
Study: 9435041
Drug: Meropenem (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (3.0 g/day)
Study: 2442551
Drug: Lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 20 mg (increased to 80 mg if necessary)
Study: 2442551
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg (increased to 200 mg if necessary)
Study: 2442551
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 12.5 or 25 mg added after 12 weeks if necessary
Study: 24619576
Drug: 10% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% lidocaine sprayed on the laryngoscope blade (group L)
Study: 20618964
Drug: Chicory root
Normalized name: Chicory Root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chicory root extract (600 mg/day, 1200 mg/day, 1800 mg/day for 1 month)
Study: 16259626
Drug: Resource-oriented music
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resource-oriented music therapy (biweekly sessions for three months)
Study: 9532410
Drug: Interleukin-2-based therapy
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interleukin-2-based therapy (same as originally used)
Study: 9532410
Drug: Different interleukin-2-based
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Different interleukin-2-based therapy (including tumor-infiltrating lymphocytes)
Study: 9532410
Drug: Interleukin-2-based therapy
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interleukin-2-based therapy (initial response)
Study: 9532410
Drug: Interleukin-2-based therapy
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interleukin-2-based therapy (partial response)
Study: 9532410
Drug: Interleukin-2-based therapy
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interleukin-2-based therapy (complete response)
Study: 7498222
Drug: 99mTc‐L,L‐EC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc‐L,L‐EC
Study: 25125271
Drug: Self-administered HIV/HCV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered HIV/HCV risk assessment plus brief intervention about drug misuse and screening for HIV/HCV
Study: 25125271
Drug: Self-administered HIV/HCV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered HIV/HCV risk assessment alone (control)
Study: 17564103
Drug: Propiverine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverine alone (monotherapy group, n = 52)
Study: 17564103
Drug: Propiverine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverine plus urapidil (combination group, n = 48)
Study: 11466989
Drug: Physical training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical training programme (twice a week for three months)
Study: 9465812
Drug: Preoperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative administration of two injections of leuprolide acetate 28 days apart (group A)
Study: 7486614
Drug: CNS 1102
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CNS 1102 (aptiganel hydrochloride) administered in doses of up to 100 micrograms/kg
Study: 7486614
Drug: CNS 1102
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CNS 1102 administered as a 15-minute intravenous infusion, a 15-minute loading intravenous infusion followed by a 4-hour maintenance infusion, or as a fixed-dose intravenous bolus over 90 seconds
Study: 2650735
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g margarine added to soup
Study: 2650735
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g margarine added to mashed potato
Study: 964056
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment with neomycin and bacitracin for 4 days preoperatively
Study: 964056
Drug: Mechanical and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical and dietary preparation only (Control)
Study: 964056
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment with neomycin and bacitracin
Study: 31059146
Drug: Hydrocortisone (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (lower dose) in secondary adrenal insufficiency